Source:http://linkedlifedata.com/resource/pubmed/id/20063133
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-3-18
|
| pubmed:abstractText |
We prospectively compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy as a post-remission therapy in a multicenter trial (JALSG AML97) of adult patients with intermediate or poor risk acute myeloid leukemia (AML). Of 503 patients aged 15-50 years old registered between December 1997 and July 2001, 392 achieved complete remission (CR). CR patients classified in the intermediate or poor risk group using a new scoring system were tissue typed. Seventy-three with and 92 without an HLA-identical sibling were assigned to the donor and no-donor groups. Of 73 patients in the donor group, 38 (52%) received allo-HSCT during CR1 and 17 (23%) after relapse. Intention-to-treat analysis revealed that the relapse incidence was reduced in the donor group (52 vs. 77%; p = 0.008), and the disease-free survival (DFS) improved (39 vs. 19%; p = 0.016), but overall survival (OS) was not significantly different (46 vs. 29%; p = 0.088). The OS benefit was seen in the patients aged 36-50 years old (49 vs. 24%; p = 0.031), suggesting an advantage of allo-HSCT among older patients with leukemia that is more resistant to chemotherapy than that among younger patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1865-3774
|
| pubmed:author |
pubmed-author:AsouNorioN,
pubmed-author:EmiNobuhikoN,
pubmed-author:HondaSumihisaS,
pubmed-author:KishimotoYujiY,
pubmed-author:MatsudaShinS,
pubmed-author:MitaniKinukoK,
pubmed-author:MiyawakiShuichiS,
pubmed-author:MiyazakiYasushiY,
pubmed-author:OgawaYoshiakiY,
pubmed-author:OhnoRyuzoR,
pubmed-author:OhtakeShigekiS,
pubmed-author:SakamakiHisashiH,
pubmed-author:TakahashiMasatomoM,
pubmed-author:YagasakiFumiharuF
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
91
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
284-92
|
| pubmed:meshHeading |
pubmed-meshheading:20063133-Adolescent,
pubmed-meshheading:20063133-Adult,
pubmed-meshheading:20063133-Age Distribution,
pubmed-meshheading:20063133-Antimetabolites, Antineoplastic,
pubmed-meshheading:20063133-Child,
pubmed-meshheading:20063133-Child, Preschool,
pubmed-meshheading:20063133-Cytarabine,
pubmed-meshheading:20063133-Drug Resistance, Neoplasm,
pubmed-meshheading:20063133-Female,
pubmed-meshheading:20063133-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20063133-Humans,
pubmed-meshheading:20063133-Incidence,
pubmed-meshheading:20063133-Leukemia, Myeloid, Acute,
pubmed-meshheading:20063133-Male,
pubmed-meshheading:20063133-Middle Aged,
pubmed-meshheading:20063133-Recurrence,
pubmed-meshheading:20063133-Risk Factors,
pubmed-meshheading:20063133-Survival Analysis,
pubmed-meshheading:20063133-Transplantation, Homologous
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
|
| pubmed:affiliation |
Division of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. sakamaki-h@cick.jp
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|